|
Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with mRCC. |
|
|
|
|
Stock and Other Ownership Interests - Ipsen |
|
Travel, Accommodations, Expenses - Ipsen |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Sanofi |
|
Consulting or Advisory Role - Ipsen |
|
|
|
Stock and Other Ownership Interests - Exelixis |
Research Funding - Exelixis/Ipsen |
Travel, Accommodations, Expenses - Exelixis |
|
|
|
Stock and Other Ownership Interests - McKesson |
|
|
|
|
Stock and Other Ownership Interests - McKesson |
Consulting or Advisory Role - Ipsen |
|
|
|
Consulting or Advisory Role - Janssen Biotech |